Reaction
Invasive Breast Carcinoma reporting signals
As of the last recalculation, Invasive Breast Carcinoma appears in 408 FAERS reports alongside 8 co-occurring drug terms. The strongest observed disproportionality signal is RIBOCICLIB (PRR 71.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ribociclib | 40 | 71.6 | 71.7 |
| Goserelin | 17 | 67.4 | 67.4 |
| Fulvestrant | 30 | 49.9 | 50.0 |
| Letrozole Tablets | 42 | 49.5 | 49.6 |
| Letrozole | 47 | 43.9 | 43.9 |
| Anastrozole Tablets | 15 | 37.0 | 37.0 |
| Ado-Trastuzumab Emtansine | 4 | 24.4 | 24.4 |
| Alpelisib | 4 | 23.6 | 23.6 |